34 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
HMG/Courtland Properties, Inc. (NYSE: HMG) shares surged 133% to $27.80.
VBL Therapeutics Shares Drop As Pending Clearance Of New Batches Cancer Gene Therapy Hit Recruitment In Ovarian Cancer Trial
The FDA notified VBL Therapeutics Ltd (NASDAQ: VBLT) that clearance of new VB-111 batches for use in the U.S. is currently pending, as review by the Chemistry, Manufacturing, and Controls (CMC) group is still ongoing.
VBL Therapeutics Says Was Notified By FDA That Clearance For New VB-111 Batches Is Pending Completion Of A Technical Review; Co. Expects Shortage Of Study Drug Supply for US And Has Paused Patient Recruitment
VBL Therapeutics (NASDAQ:VBLT) today provided an update on its ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111), for the treatment of platinum-resistant ovarian cancer.
The Company was
55 Biggest Movers From Yesterday
Gainers
DLocal Limited (NASDAQ: DLO) shares jumped 54.2% to close at $32.39 on Thursday. DLocal raised around $92.6 million from the sale of 4.4 million shares in its IPO.
46 Stocks Moving In Thursday’s Mid-Day Session
Gainers
GTT Communications, Inc. (NYSE: GTT) shares jumped 66% to $4.16 on abnormally-high volume. The company’s stock also jumped over 57% on Wednesday.
Roth Capital Maintains Buy on Vascular Biogenics, Raises Price Target to $7
Roth Capital analyst Jonathan Aschoff maintains Vascular Biogenics (NASDAQ:VBLT) with a Buy and raises the price target from $5 to $7.
VBL Therapeutics Stock Jumps on Adding PFS as Second Independent Primary Endpoint in Ovarian Cancer Gene Therapy Trial
VBL Therapeutics Ltd (NASDAQ:VBLT) has amended the primary endpoint in the OVAL Phase 3 registration-enabling study of VB-111 (ofranergene obadenovec) gene therapy for…
VBL Therapeutics Announces Addition of Progression Free Survival As A Second Primary Endpoint in OVAL, A Phase 3 Registration Enabling Study Of VB-111 In Ovarian Cancer
Second primary endpoint added following discussion with the U.S. Food and Drug Administration
Successfully meeting either PFS or OS primary endpoints expected to be sufficient for submitting a BLA for potential full
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 10)
Earnings Scheduled For May 11, 2021
Companies Reporting Before The Bell
• Oxford Lane Capital (NASDAQ:OXLC) is estimated to report earnings for its fourth quarter.